Harbour Trust & Investment Management Co Purchases 295 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Harbour Trust & Investment Management Co raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,672 shares of the medical research company’s stock after purchasing an additional 295 shares during the quarter. Harbour Trust & Investment Management Co’s holdings in Thermo Fisher Scientific were worth $8,153,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Angeles Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 0.6% in the 4th quarter. Angeles Wealth Management LLC now owns 3,943 shares of the medical research company’s stock valued at $2,051,000 after buying an additional 22 shares during the period. Newbridge Financial Services Group Inc. bought a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $52,000. Kestra Private Wealth Services LLC increased its stake in shares of Thermo Fisher Scientific by 10.4% during the 4th quarter. Kestra Private Wealth Services LLC now owns 11,914 shares of the medical research company’s stock worth $6,198,000 after purchasing an additional 1,118 shares during the last quarter. Howland Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific by 2.7% during the 4th quarter. Howland Capital Management LLC now owns 79,771 shares of the medical research company’s stock worth $41,530,000 after acquiring an additional 2,098 shares during the last quarter. Finally, Empowered Funds LLC lifted its position in Thermo Fisher Scientific by 17.8% during the fourth quarter. Empowered Funds LLC now owns 11,408 shares of the medical research company’s stock worth $5,935,000 after acquiring an additional 1,720 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Down 0.2 %

Shares of Thermo Fisher Scientific stock opened at $571.44 on Monday. The stock has a 50 day moving average of $547.34 and a 200 day moving average of $572.26. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The firm has a market capitalization of $218.58 billion, a price-to-earnings ratio of 34.57, a PEG ratio of 3.18 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share repurchase plan on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Stifel Nicolaus decreased their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Wells Fargo & Company increased their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Robert W. Baird decreased their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Citigroup increased their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a research note on Friday, January 31st. Finally, UBS Group increased their price objective on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Four analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $658.00.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the sale, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the sale, the executive vice president now directly owns 16,363 shares in the company, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 20,125 shares of company stock worth $11,231,699. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.